DexCom -- How the Business Works

The DexCom Business Model

Duopoly dynamics: Abbott and DexCom together control ~91% of the global CGM market. Barriers to entry are very high: FDA PMA regulatory pathway, manufacturing scale, multi-year clinical evidence requirements, payer reimbursement relationships, and deep integration into automated insulin delivery (AID) ecosystems. Medtronic (~7%) is captive to its own pump users. New entrants like Senseonics (implantable) and Chinese CGMs remain niche. The recurring sensor replacement cycle (every 10-15 days) creates a razor/blade revenue model with high retention. DexCom dominates the premium prescribed segment in the US, while Abbott leads in volume-driven international and pharmacy channels.

Revenue by Geography and Product -- FY2025 (~$4.66B)

Growth Vectors and Timeline to Materiality

CGM Penetration by Patient Segment -- Massive Whitespace

TAM: Global CGM market is ~$13.3B today, projected to reach $31B+ by 2031 (15% CAGR). 38.4M Americans have diabetes (15.8% adult prevalence, up from 9.7% in 1999-2000). Global diabetes cases projected to reach 643M by 2030. The penetration gap is the core investment thesis -- even in the most mature segment (Type 1), 70% of patients are not yet on CGM. In Type 2 (the largest population), penetration is negligible.

1. Duopoly market structure with high barriers to entry. The CGM market is a tight duopoly: Abbott (56%) + DexCom (35%) = 91% combined share. Barriers to entry are extraordinarily high -- FDA PMA regulatory pathway requires years of clinical trials, manufacturing scale for billions of sensor units, established reimbursement relationships with payers, and integration into the automated insulin delivery ecosystem. No new meaningful entrant has emerged in over a decade.

2. AID ecosystem lock-in. DexCom G7 is integrated with Omnipod 5, Tandem t:slim, and other insulin pump systems for automated insulin delivery. Once a Type 1 patient is on a DexCom-paired AID system, switching CGM requires re-training, physician approval, and recalibration of the algorithm. This creates very high switching costs in the highest-value patient segment. DexCom dominates AID pairings in the US.

3. Recurring razor/blade revenue model. CGM sensors are replaced every 10-15 days, creating a highly predictable recurring revenue stream (~97% of total revenue is sensors). Once a patient starts on CGM, adherence rates are high -- especially in prescribed/reimbursed channels where out-of-pocket cost is minimal. Patient lifetime value is substantial given chronic disease management over decades.

4. Clinical evidence and regulatory moat. DexCom has the deepest clinical evidence base in CGM, with landmark studies (MOBILE, DIaMonD) demonstrating A1C improvement and outcomes benefits. This evidence underpins payer reimbursement decisions and physician prescribing behavior. New entrants would need to replicate years of clinical trial investment.

5. First-mover advantage in OTC. Stelo is the first FDA-cleared OTC CGM, giving DexCom a head start in the wellness/non-diabetic category. Building consumer brand awareness and retail distribution relationships (Amazon, Life Time, pharmacy) before Abbott launches its OTC offering creates a meaningful early-mover advantage in a nascent market.

Abbott competitive pressure: Abbott Libre generated $7.6B in 2025 (+17%) and holds ~56% global share vs. DexCom at ~35%. Abbott competes aggressively on price, pharmacy channel access, and international distribution. Libre 3 approaches G7 accuracy, and Libre 4 could narrow the technology gap further. Abbott is gaining share internationally and in the US pharmacy channel. The duopoly is real but DexCom is the smaller partner.

100% single-category concentration: DexCom derives virtually 100% of revenue from CGM. Non-CGM revenue was just $3M in Q1 2025. Any structural disruption to CGM demand -- whether from GLP-1-driven diabetes remission at scale (uncertain but possible long-term), alternative glucose monitoring technologies, or reimbursement changes -- would impact the entire business with no diversification buffer.

Medicare coverage timing uncertainty: Type 2 non-insulin Medicare coverage has been described as "imminent" for years; further delays are possible. If the CMS proposal slips beyond 2026, the largest near-term catalyst would be deferred. Coverage scope and reimbursement rates remain unknown until the final rule is published.

Management credibility gap: The Q2 2024 guide-down (~$250M self-inflicted cut from botched salesforce expansion) was a top-tier credibility event. CEO Sayer departed end of 2025 (medical leave). New CEO Leach is a 20-year insider and former CTO -- technically strong but unproven as a public company CEO. Supply chain issues in 2025 (damaged shipments, freight/scrap) created a second operational blemish before resolution in Q4. Trust recovery is ongoing but incomplete.

FDA warning letter overhang: G7 received an "adulterated" classification from the FDA, generating a warning letter and class action lawsuits. While not a product recall and likely resolvable, the regulatory overhang creates headline risk and investor uncertainty until formally resolved. This adds to the negative sentiment that has pushed the stock down 31% to near 52-week lows.